Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH
NCT07722884
Benign Prostatic Hyperplasia, Efficacy
Cairo, Cairo Governorate, Egypt
View Trial DetailsNCT Number: NCT05292235
This is a prospective data registry to assess the treatment outcomes and complications of different treatment approaches in our hospital clusters.
Interested in participating?
Request Info18 year and older
Male
Observational
Alice Ho Miu Ling Nethersole Hospital, Hong Kong
Benign prostatic hyperplasia (BPH) is a very common disease affecting men. Patients with BPH may present with voiding symptoms including hesitancy, intermittence, slow stream and sensation of incomplete emptying, and storage symptoms including urinary frequency, urgency and nocturia. Patients may also suffer from complications including urinary retention, recurrent urinary tract infection, bladder stone formation and obstructive uropathy. For patients who have lower urinary tract symptoms refractory to medications, or those who suffer from complications of BPH, transurethral prostatectomy should be considered.
Surgical intervention options have evolved from electrosurgical resection to the use of lasers for enucleation and ablation [1]. Aquablation and Rezum system are new minimally invasive surgical technology for BPH management. [2,3,4]. Different treatment approaches will result in different treatment successful rate and also potential adverse effects to patients.
However, large-scale studies investigating the different modalities of surgical treatment of BPH are lacking. Therefore, a prospective data registry is created to assess the perioperative surgical outcomes for different surgical treatment of BPH.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline, 3 months after surgical treatment for BPH
Change in total scores in International Prostate Symptom Score (ranges from 0 to 35) questionnaires
Time frame: Baseline, 3 months after after surgical treatment for BPH
Change in urodynamic function assessed by Uroflowmetry
Time frame: Post operation 30 days after surgical treatment for BPH
The 30-day complications will be graded according to the Clavien-Dindo classification
Contact information is provided by the study sponsor or research team.
Chinese University of Hong Kong
Other
A Prospective Assessment of the Perioperative Parameter and Treatment Outcomes of Surgical Treatment for Benign Prostate Hyperplasia in Hong Kong
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07722884
Benign Prostatic Hyperplasia, Efficacy
Cairo, Cairo Governorate, Egypt
View Trial DetailsNCT07694752
Benign Prostatic Hyperplasia, Genital Diseases
Taizhou, Jiangsu, China
View Trial DetailsNCT06511141
Benign Prostatic Hyperplasia, Female Urogenital Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06312722
Benign Prostatic Hyperplasia, Genital Diseases
Little Rock, Arkansas, United States
View Trial Details